Abstract:A combination administration of chemical agents was highlighted to treat tumors. Recently, tumor cell has been found to be different from normal cell in metabolic manner. Most of cancer cells prefer aerobic glycolysis to mitochondrial oxidative phosphorylation (OXPHOS) to satisfy energy and biomass synthesis requirement to survive, grow and proliferate, which provides novel and potential therapeutic targets for chemotherapy. Here, 2-deoxy-d-glucose (2-DG), a potent inhibitor of glucose metabolism, was used to inhibit glycolysis of tumor cells; α-tocopheryl succinate (α-TOS), a water-insoluble vitamin E derivative, was chosen to suppress OXPHOS. Our data demonstrated that the combination treatment of 2-DG and α-TOS could significantly promote the anti-tumor efficiency in vitro compared with administration of the single drug. In order to maximize therapeutic activity and minimize negative side effects, a co-delivery nanocarrier targeting folate receptor (FR) was developed to encapsulate 2-DG and α-TOS simultaneously based on our previous work. Transmission electron microscope, dynamic light scattering method and UV-visible spectrophotometers were used to investigate morphology, size distribution and loading efficiency of the α-TOS-2-DG-loaded and FR-targeted nanoparticles (TDF NPs). The TDF NPs were found to possess a layer-by-layer shape, and the dynamic size was <100 nm. The final encapsulation efficiencies of α-TOS and 2-DG in TDF NPs were 94.3%±1.3% and 61.7%±7.7% with respect to drug-loading capacities of 8.9%±0.8% and 13.2%±2.6%, respectively. Almost no α-TOS release was found within 80 h, and release of 2-DG was sustained and slow within 72 h. The results of FR binding assay and fluorescence biodistribution revealed that TDF NPs could target FR highly expressed on tumor cell in vitro and in vivo. Further, in vivo anti-tumor experiments showed that TDF NPs had an improved biological function with less toxicity. Thus, our work indicates that the co-delivery TDF NPs have a great potential in tumor therapy.

Tumor Specific Delivery And Therapy By Double-Targeted Nanostructured Lipid Carriers With Anti-Vegfr-2 Antibody

Tumor-Specific Delivery and Therapy by Double-Targeted DTX-CMCS-PEG-NGR Conjugates

Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes

Co-delivery Nanocarriers Targeting Folate Receptor and Encapsulating 2-Deoxyglucose and Α-Tocopheryl Succinate Enhance Anti-Tumor Effect in Vivo.

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.

Enhanced Nanodrug Delivery to Solid Tumors Based on a Tumor Vasculature-Targeted Strategy

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

Dual Receptor-Specific Peptides Modified Liposomes As VEGF Sirna Vector for Tumor-Targeting Therapy

Enhanced Anticancer Efficacy of Dual Drug-Loaded Self-Assembled Nanostructured Lipid Carriers Mediated by pH-Responsive Folic Acid and Human-Derived Cell Penetrating Peptide dNP2

Targeted Delivery of Transferrin and TAT Co-Modified Liposomes Encapsulating Both Paclitaxel and Doxorubicin for Melanoma.

Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation

Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis.

A novel delivery vector for targeted delivery of the antiangiogenic drug paclitaxel to angiogenic blood vessels: TLTYTWS-conjugated PEG–PLA nanoparticles

Tumor Targeted Nanostructured Lipid Carrier Co-Delivering Paclitaxel and Indocyanine Green for Laser Triggered Synergetic Therapy of Cancer

Targeted Delivery of a Combination Therapy Consisting of Combretastatin A4 and Low-Dose Doxorubicin Against Tumor Neovasculature.

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.

Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery

Anti-Tumor Efficacy of C(Rgdfk)-Decorated Polypeptide-Based Micelles Co-Loaded with Docetaxel and Cisplatin

Novel Drug Delivery Liposomes Targeted with a Fully Human Anti-Vegf165 Monoclonal Antibody Show Superior Antitumor Efficacy in Vivo.

Enhanced in Vivo Antitumor Efficacy of Dual-Functional Peptide-Modified Docetaxel Nanoparticles Through Tumor Targeting and Hsp90 Inhibition.

RGD(Arg-Gly-Asp) Internalized Docetaxel-Loaded Ph Sensitive Liposomes: Preparation, Characterization and Antitumor Efficacy in Vivo and in Vitro.